A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront

- For non-US Heathcare Media and Medical Media only

Ingelheim, Germany, August 30, 2010 – The European Society of Cardiology (ESC) today issued revised practice guidelines for the management of atrial fibrillation (AF), including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).